Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 24,78 € (-17,59%). La mediana è 23,23 € (-22,75%).
| Acquista |
9 |
| Mantieni |
13 |
| Vendi |
2 |
Notizie Vai al feed delle notizie
Doximity falls after downgrade by Freedom Capital
Doximity shares dropped 5.6% after Freedom Capital cut its rating from "buy" to "hold" while raising the price target from $24 to $27. The company reported Q1 results above expectations and raised its revenue outlook but lowered its EBITDA forecast to fund increased investments in AI development and computing power. Freedom Capital reduced its mid-point EBITDA estimate for 2027 from $329 million to $319 million and cited a balanced risk-reward profile for the downgrade; competition from Epic and OpenEvidence and tight pharma budgets remain risks, while AI search contracts are showing early positive momentum. » Altro su de.investing.com
Doximity CEO sells 8,505 shares to cover tax withholding after equity vesting
Doximity CEO Jeffrey Tangney sold 8,505 Class A shares on August 15 to satisfy tax withholding from vested awards, a non-discretionary transaction that reduced his direct stake by roughly 0.3% to 2,531,955 shares (about 1% ownership). The sale does not reflect a market judgment by Tangney and three other insiders had similar withholdings the same day. Company results show slowing top-line growth, margin pressure from rising AI compute costs, and a guidance lull as AI-related revenue recognition is expected later in the year, while the stock has fallen over 60% in the past year. » Altro su finance.yahoo.com
Doximity granted president 150,000 options as he sold small stake to cover taxes
Doximity president Steven L. Zatz sold 4,482 Class A shares in a non‑discretionary sell‑to‑cover to satisfy tax withholding after RSU vesting and retains 51,864 shares (~$1.29m at $24.80). The company granted Zatz 150,000 options on July 22 with a $20.49 strike that begin vesting in July 2027, tying future pay to stock appreciation. Doximity reported Q2 revenue of $156.6m (7% growth) and raised its full‑year range while AI compute costs lowered gross margin to 87.5% and adjusted EBITDA fell 6% to $74.8m; management says higher‑than‑expected AI usage should drive future revenue recognition. Investors should note the option grant links executive upside to stock performance as AI‑related costs and upcoming AI revenue recognition will affect margins and earnings. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 137,23 Mln | 10,85% |
| Utile lordo | 116,47 Mln | 5,50% |
| Utile netto | 21,31 Mln | 52,90% |
| EBITDA | 39,12 Mln | 31,11% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 5,29 Mld € |
Numero di azioni | 178,25 Mln |
Massimo/minimo a 52 settimane | 61,65 € - 15,32 € |
| Dividendi | No |
Beta | 1,22 |
Rapporto P/E | 37,35 |
Rapporto PEG | -1,30 |
Rapporto P/B | 6,62 |
Rapporto P/S | 9,04 |
Profilo aziendale
Doximity, Inc. gestisce una piattaforma digitale basata sul cloud per i professionisti medici negli Stati Uniti. La piattaforma dell'azienda offre ai suoi membri strumenti pensati per i professionisti medici, che consentono loro di collaborare con i colleghi, coordinare l'assistenza ai pazienti, effettuare visite virtuali ai pazienti, restare aggiornati sulle ultime notizie e ricerche in campo medico e gestire la propria carriera. Serve principalmente case farmaceutiche e sistemi sanitari. L'azienda era precedentemente nota come 3MD Communications, Inc. e ha cambiato denominazione in Doximity, Inc. nel giugno 2010. Doximity, Inc. è stata costituita nel 2010 e ha sede a San Francisco, California.
| Nome | DOXIMITY INC DL-,001 |
| CEO | Jeffrey A. Tangney |
| Sede centrale | San Francisco,
ca Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Tecnologia sanitaria |
| Quotazione in borsa | 02/01/2008 |
| Dipendenti | 880 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | DOCS |